Eyenovia, Inc. announced that the company?s facility in Redwood City, California successfully completed FDA inspection for approval as a commercial manufacturing facility. The Redwood City facility will primarily be used for final assembly, packaging and labeling activities in support of Mydcombi, the first and only fixed combination of tropicamide and phenylephrine for in-office and pre-surgical pupil dilation utilizing Optejet? technology.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8045 USD | -6.99% | -14.18% | -61.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.32% | 44.08M | |
+32.62% | 698B | |
+26.51% | 568B | |
-4.47% | 358B | |
+19.55% | 328B | |
+3.37% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+9.04% | 165B |
- Stock Market
- Equities
- EYEN Stock
- News Eyenovia, Inc.
- Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility